Quick answer
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.24B and net income of $210.0M for the fiscal year ended 2025-12-31, up 4.3% from $1.19B the year before, per its 10-K filed with the SEC on 2026-02-26. Long-term debt stood at $290.0M.
Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)
| Fiscal year | Revenue | Net income | Long-term debt |
|---|---|---|---|
| 2025 (FY ending 2025-12-31) | $1.24B | $210.0M | $290.0M |
| 2024 (FY ending 2024-12-31) | $1.19B | $7.0M | $315.0M |
| 2023 (FY ending 2023-12-31) | $1.09B | -$126.0M | $237.0M |
| 2022 (FY ending 2022-12-31) | $901.0M | -$44.0M | — |
Frequently asked questions
What is Indivior Pharmaceuticals, Inc.'s annual revenue?
Indivior Pharmaceuticals, Inc. (INDV) reported revenue of $1.24B and net income of $210.0M for the fiscal year ended 2025-12-31, up 4.3% from $1.19B the year before, per its 10-K filed with the SEC on 2026-02-26. Long-term debt stood at $290.0M.
What is INDV's profit margin?
Indivior Pharmaceuticals, Inc.'s net margin was 16.9% in the fiscal year ended 2025-12-31.
Related
- IIIN revenue, net income and debt history (Insteel Industries Inc.)
- ILMN revenue, net income and debt history (Illumina, Inc.)
- INCY revenue, net income and debt history (Incyte Corporation)
- INGM revenue, net income and debt history (Ingram Micro Holding Corp)
- INMB revenue, net income and debt history (Inmune Bio Inc.)
- INSM revenue, net income and debt history (Insmed Inc)
- INTA revenue, net income and debt history (Intapp, Inc.)
- INTC revenue, net income and debt history (Intel Corp)
Last updated Oct 23, 2026, 7:21 AM ET. Data only, not financial or tax advice.
Related answers
Tools & live data
What's Moving Right Now
#1 Nasdaq-100 moverAMD $507.93 -8.10%Nasdaq, as of Oct 22, 2026 4:15 PM ET
Trading halts18 halts in Nasdaq's current feedNasdaq Trader feed, checked Oct 23, 7:30 AM ET
Earnings & SEC 8-Ks14 companies report Oct 23 · 8-Ks todayNasdaq earnings calendar, SEC EDGAR